ENGLEWOOD CLIFFS, N.J. July 31 /PRNewswire-FirstCall/ -- EpiCept Corporation announced today that it has appointed Michael C. Chen as the Company’s Vice President for Global Business Development. He brings to EpiCept a successful track record in business development and deep experience in licensing and acquiring technologies and brand management for the life sciences industry. Prior to joining EpiCept, Mr. Chen was Executive Vice President of Sales and Marketing at the SpyGlass Group, a healthcare consulting firm. He has also served in several senior management positions at Johnson & Johnson and elsewhere in the pharmaceutical industry.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO)
“We are pleased to have someone of Michael’s caliber join EpiCept, and look forward to benefiting from his expertise in licensing and product development negotiation,” stated Jack V. Talley, President and Chief Executive Officer of EpiCept.
Prior to the SpyGlass Group, Mr. Chen served as Executive Director of Worldwide Licensing and Acquisitions at Johnson & Johnson, where he structured, negotiated and closed a number of transactions, including several major licenses in the prescription dermatologic market. Additionally, he developed and managed R&D alliances with several worldwide companies. Before Johnson & Johnson, he served as Vice President, Business Development at Synaptic Pharmaceutical Company. At Synaptic, he led the business development efforts, which successfully licensed the company’s’ proprietary drug targets and secured partners for the development of novel neuro-pharmaceuticals. Prior to Synaptic, Mr. Chen served as the Director of Business Development for Ciba-Geigy Corporation where he was involved with strategic planning and the evaluation and negotiation of business arrangements for an extensive range of treatments, which include the anti-inflammatory and oncology areas.
Mr. Chen received his MBA from the Harvard Business School, his Masters in Chemical Engineering from the Massachusetts Institute of Technology and his Bachelors in Chemical Engineering from Cornell University.
About EpiCept Corporation
EpiCept is an emerging pharmaceutical company focused on unmet needs in the treatment of pain and cancer. The company has a staged portfolio with several pain therapies in late-stage clinical trials, and a lead oncology compound (for AML) with demonstrated efficacy in a Phase III trial; the compound is intended for commercialization in Europe. EpiCept is based in New Jersey, and the company’s R&D team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in EpiCept’s periodic reports and other filings with the SEC.
EPCT - GEN
Photo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGOEpiCept Corporation
CONTACT: Robert W. Cook of EpiCept Corporation, +1-201-894-8980,rcook@epicept.com; or Francesca T. DeVellis of Feinstein Kean Healthcare,+1-617-577-8110, francesca.devellis@fkhealth.com, for EpiCept Corporation
Web site: http://www.epicept.com/
